Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1CNS 1Breast 1

Conditions

Brain Neoplasms 290Glioblastoma 260Glioma 202Neuroblastoma 88Neoplasms 62Astrocytoma 56Central Nervous System Neoplasms 54Medulloblastoma 48Breast Neoplasms 44Melanoma 40Sarcoma 39Meningioma 39Neurofibromatosis 1 38Carcinoma, Non-Small-Cell Lung 38Lung Neoplasms 37Ependymoma 36Osteosarcoma 31Rhabdomyosarcoma 30Neoplasm Metastasis 28Sarcoma, Ewing 27Rhabdoid Tumor 27Diffuse Intrinsic Pontine Glioma 27Recurrence 26Oligodendroglioma 23Gliosarcoma 22Wilms Tumor 21Pancreatic Neoplasms 21Pheochromocytoma 20Hepatoblastoma 20Neurofibroma, Plexiform 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anophthalmia with pulmonary hypoplasia × CNS × 90 days × Clear all
NCT06458712 2026-05-27

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Duke Street Bio Ltd

Phase 1 Recruiting
180 enrolled
CNS

Kenny-Caffey syndrome, Type 1, Anophthalmia with pulmonary hypoplasia, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡